Skip to main content

Day: September 23, 2025

Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 23, 2025, at 14:00 CEST / 13:00 BST / 08:00 BST. Details are at the end of this news release Pratteln, Switzerland, September 23, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the Company’s financial results for the six months ended June 30, 2025, reports on progress with AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) and provides updates on its corporate and financing initiatives. HighlightsTotal revenue increased 70% to CHF 24 million (H1 2024: CHF 14.1 million) driven by strong sales growth in launched markets in addition to growing royalty and product supply revenues Product sales increased 76% to CHF 11.6 million (H1 2024: CHF 6.6 million), led by Germany and Austria with first contributions from the UK following...

Continue reading

China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies

SHENZHEN, CHINA, Sept. 23, 2025 (GLOBE NEWSWIRE) — China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the “Agreements”) with Chongqing Genrix Biopharmaceutical Co., Ltd. (“Genrix Bio”) for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, “Vecantoxatug”) indicated for passive immunization against tetanus and Silevimig Injection (GR1801, “Silevimig”) indicated for passive immunization following suspected rabies virus exposure, respectively. In accordance with the Agreements, the Group has obtained exclusive commercialization rights for these two products in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle...

Continue reading

Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares

VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the pricing of its previously announced public offering (the “Offering”) of 12,727,273 common shares of the Company (the “Common Shares”) at a price to the public of US$5.50 per Common Share for gross proceeds of approximately US$70 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the Offering. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,909,090...

Continue reading

Big 5 Sporting Goods Corporation Postpones Special Meeting of Stockholders; Urges Stockholders to Continue Voting “For” the Merger and Related Proposals at the Special Meeting

$1.45 per share all-cash consideration contemplated by the proposed merger with Worldwide Golf (the “Merger”) is the conclusion of an eight-month process with multiple parties that resulted in three proposals. Postpones Special Meeting of Stockholders to September 26, 2025. Your vote is very important, regardless of the number of shares that you own. The transaction cannot be completed unless the Merger proposal is approved by the holders of at least a majority of the issued and outstanding shares of Big 5 common stock. Independent proxy advisory firms ISS and Glass Lewis both recently issued recommendations in favor of the Merger. Previously submitted votes remain valid with no further action required. If you have any questions about voting, please call Innisfree, our proxy solicitor, toll-free at (877) 687-1873 if in North America,...

Continue reading

Platinum Analytics Cayman Limited Announces Closing of Its Initial Public Offering and Full Exercise of Over Allotment

Singapore, Sept. 22, 2025 (GLOBE NEWSWIRE) — Platinum Analytics Cayman Limited (the “Company” or “PLTS”), a software developer specializing in the provision of FX trading software development solutions, data analytics solutions and technology development solutions to financial institutions with a strategic focus on serving Asia and other emergent markets, today announced the closing of its initial public offering (the “Offering”) of 2,300,000 Class A ordinary shares (the “Ordinary Shares”), which included the underwriters’ full exercise of their over-allotment option, at a public offering price of $4.00 per share for gross proceeds of $9,200,000, before deducting underwriting discounts and offering expenses. The Offering closed on September 22, 2025 and the Ordinary Shares commenced trading on the Nasdaq Capital Market on September...

Continue reading

Minute Media Acquires VideoVerse, Owner of Magnifi, A Leading AI Sports Video Technology Platform

The acquisition comes a year after a series of robust sports technology and content additions to Minute Media’s portfolio, culminating with a 360-degree solution for rightsholders, leagues, teams, publishers, and marketers NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) — Minute Media, a leading global technology and sports content company, today announced its acquisition of VideoVerse. VideoVerse’s leading product, Magnifi, an AI-driven SaaS technology platform, enables content owners and rights holders to automatically detect key moments, create highlights in real time, and distribute compelling short-form video content efficiently. The addition of VideoVerse will enable Minute Media to provide unprecedented value to the sports content ecosystem, furthering both parties’ partnership capabilities. With this acquisition, Minute Media...

Continue reading

Microvast at BICES 2025: Electrifying Construction Machinery

STAFFORD, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) — Microvast Holdings, Inc. (NASDAQ: MVST) (“Microvast”, the “Company” or “we”), a global leader in advanced battery technologies, will showcase its suite of high-performance battery products at the Beijing International Construction Machinery, Building Material Machines, and Mining Machines Exhibition & Symposium (BICES 2025). The event will be held at the China International Exhibition Center’s Shunyi Exhibition Hall September 23-26, 2025. At booth E 2170, Microvast will present efficient power solutions for applications including all-electric and hybrid mining trucks. Addressing the high-intensity demands of construction machinery, Microvast will highlight its fast-charging battery solutions. Microvast’s HpTO-37Ah, MpCO-48Ah, and HpCO-55Ah battery models are engineered...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.